Liraglutide and NLY01 increase GLP1 and GLP1 receptor levels, respectively [32, 51], whereas semaglutide does not affect GLP1 receptor expression in 3xTg-AD mice [49]. This evidence concerns the gene GCG and Alzheimer disease.